Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ashish Bhatia

Procedural Dermatology Itasca, IL Medical Doctor

NPI 1073595690 CMS profile 48239

550 E Devon Ave Ste 200, Itasca, IL 60143

Open in the dashboard

General payments

$434,331

732 records reported · program years 2019–2025

Research payments

$116,070

Paid to them · 27 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$205,875 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Ashish Bhatia of Itasca, IL is reported in the CMS Open Payments database as having received $434,331 across 732 general payments and $116,070 in research payments paid to them. Separately, studies naming them as principal investigator received $205,875 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Procedural Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $136,598 196
2025 Research $2,918 12
2024 General $105,362 137
2024 Research $2,387 1
2023 General $80,525 80
2022 General $4,980 43
2022 Research $70,985 3
2021 General $26,015 79
2020 General $32,848 56
2020 Research $18,800 1
2019 General $48,003 141
2019 Research $20,981 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashish Bhatia
  • Procedural Dermatology median
  • Middle half of Procedural Dermatology
  • National median

In program year 2025, general payments to Ashish Bhatia were reported at $136,598. Among 381 Procedural Dermatology profiles paid that year, the median was $592 and the middle half received between $144 and $1,778.

Show as a table
Year Ashish Bhatia Procedural Dermatology median Middle half National median
2019 $48,003 $454 $152–$1,260 $163
2020 $32,848 $243 $90–$835 $114
2021 $26,015 $337 $102–$1,128 $132
2022 $4,980 $443 $119–$1,654 $149
2023 $80,525 $583 $137–$1,838 $160
2024 $105,362 $611 $132–$1,835 $164
2025 $136,598 $592 $144–$1,778 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arcutis Biotherapeutics, Inc. $71,021 60 payments
  2. MIMEDX Group, Inc. $54,199 37 payments
  3. STRATA Skin Sciences, Inc. $52,985 13 payments
  4. Pfizer Inc. $41,190 48 payments
  5. VYNE Pharmaceuticals Inc. $39,721 37 payments
  6. Ortho Dermatologics, a division of Bausch Health US, LLC $28,951 55 payments
  7. Regeneron Pharmaceuticals, Inc. $19,420 24 payments
  8. Solta Medical, a division of Bausch Health US, LLC $17,708 16 payments
  9. Sun Pharmaceutical Industries Inc. $16,628 36 payments
  10. Biofrontera Inc. $15,518 13 payments
  11. Other $76,990 393 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $238,572 67 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $73,345 15 payments
  3. Honoraria $43,150 16 payments
  4. Travel and Lodging $27,006 94 payments
  5. Food and Beverage $22,541 534 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $15,100 3 payments
  7. Grant $14,517 2 payments
  8. Education $100 1 payment
Products named General payments · program years 2019–2025
  1. Zoryve $60,358 47 payments
  2. XTRAC $52,985 13 payments
  3. CIBINQO $38,938 31 payments
  4. AMZEEQ $25,497 27 payments
  5. LIBTAYO $19,487 26 payments
  6. ALTRENO $17,876 32 payments
  7. ZILXI $14,287 11 payments
  8. RhodoLED XL $13,716 2 payments
  9. SILIQ $11,245 17 payments
  10. Xeomin $9,839 22 payments
  11. Other $90,419 510 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Endo Pharmaceuticals Inc. $110,766 14 payments
  2. Eli Lilly and Company $3,471 2 payments
  3. Regeneron Pharmaceuticals, Inc. $1,833 11 payments

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

508

Median for Dermatology: 534

Drug cost

$5,400

Median for Dermatology: $67,151

Branded share of claims

0%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ketoconazole Generic 293 $3,964
Mupirocin Generic 138 $1,004
Cephalexin Generic 53 $312
Cefadroxil Generic 24 $120

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 91 billing codes

Paid by Medicare

$859,695

Of which drugs: $165,233

Medicare patients

644

Average age 77

Services billed

4,400

292 women, 352 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Ischemic heart disease 31%
Diabetes 25%
Chronic kidney disease 25%
Atrial fibrillation 22%
Cancer 17%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Epieffect, per square centimeter Q4278 Office 44 451 $132,431
Epifix, per square centimeter Q4186 Office 12 142 $17,112
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 13 46 $35

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zoryve
$26,808 — —
LIBTAYO
$16,064 — —
CIBINQO
$10,989 — —
DAXXIFY
$409 — —
LITFULO
$281 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

759 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Procedural Dermatology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record